News
AIM
0.4300
+1.06%
0.0045
Weekly Report: what happened at AIM last week (0415-0419)?
Weekly Report · 2d ago
AIM ImmunoTech files to sell 9.98M shares of common stock for holders
Healthcare AIM ImmunoTech files to sell 9.98M shares of common stock for holders Apr. 19, 2024 5:12 PM ETAIM immunoTech Inc. (AIM) Stock. AIM filed a prospectus related to the offer and resale of up to 9,975,000 shares.
Seeking Alpha · 5d ago
AIM IMMUNOTECH INC - FILES PROSPECTUS RELATES TO OFFER & RESALE OF UP TO 9.97 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDER
Reuters · 5d ago
Press Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Inc. Is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. The next CEO Corner segment is now available on the company's website. The CEO Corner includes an overview of Locally Advanced Pancreatic Adenocarcinoma.
Dow Jones · 6d ago
Press Release: AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs. Dr. Lapp will help lead efforts to develop Ampligen as a potential treatment for Myalgic encephalomyelitis/chronic fatigue syndrome and long COVID. He has played a key role in AIM's AMP-511 Expanded Access Program.
Dow Jones · 04/15 12:55
Weekly Report: what happened at AIM last week (0408-0412)?
Weekly Report · 04/15 10:21
Press Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Inc. Is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. The next CEO Corner segment has been published on the company's website. The CEO Corner Segment includes a discussion of Ampligen and Keytruda in ovarian cancer.
Dow Jones · 04/11 15:00
Aim ImmunoTech Announces Positive Data From Ampligen Study In Combination With Pembrolizumab
NASDAQ · 04/10 13:17
AIM IMMUNOTECH ANNOUNCES POSITIVE TOP-LINE, PROTOCOL-PLANNED INTERIM REPORT DATA FROM THE STUDY OF AMPLIGEN COMBINED WITH PEMBROLIZUMAB FOR THE TREATMENT OF RECURRENT OVARIAN CANCER
Reuters · 04/10 12:21
Weekly Report: what happened at AIM last week (0401-0405)?
Weekly Report · 04/08 10:24
Ampligen’s Prospects in Post-COVID Fatigue and Cancer Treatment: A Strong Buy Recommendation
TipRanks · 04/03 19:05
AIM ImmunoTech Q4 EPS $(0.26) Misses $(0.15) Estimate, Sales $65.00K Beat $40.00K Estimate
AIM ImmunoTech reports quarterly losses of $0.26 per share. The company reported quarterly sales of $65.00 thousand. Missed the analyst consensus estimate of $40.50 thousand by 62.50%. The company also reported quarterly losses for the same period last year.
Benzinga · 04/03 02:58
AIM Stock Earnings: AIM ImmunoTech Misses EPS, Beats Revenue for Q4 2023
AIM ImmunoTech reported earnings per share of -26 cents for the fourth quarter of 2023. The company reported revenue of $65,000. This was 62.50% better than the analyst estimate for revenue in the same period. AIM immunoTech just reported results.
Investorplace · 04/02 15:52
AIM ImmunoTech GAAP EPS of -$0.60, revenue of $0.2M
Seeking Alpha · 04/02 11:34
AIM IMMUNOTECH REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Reuters · 04/02 11:30
Earnings Scheduled For April 2, 2024
Ocugen is estimated to report earnings for its fourth quarter. Allego is projected to report quarterly loss at $0.04 per share on revenue of $83.79 million. Cal-Maine Foods is expected to report fourth quarter earnings at $2.46 per share.
Benzinga · 04/02 10:25
Navigating the Future: Aim Immunotech’s Challenge Against Rapid Tech Evolution in Pharma
TipRanks · 04/02 06:00
Preview: AIM ImmunoTech's Earnings
AIM ImmunoTech will release its quarterly earnings report on Tuesday, 2024-04-02. The company is expected to report an earnings per share of $-0.15. Shares of AIM immunoTech were trading at $0.471 as of March 29.
Benzinga · 04/01 18:05
AIM ImmunoTech FY 2023 Earnings Preview
AIM ImmunoTech is scheduled to announce FY earnings results on Tuesday, April 2nd. The consensus EPS estimate is -$0.50 and the consensus revenue estimate is $0.16M. AIM has beaten revenue estimates 50% of the time in the last year.
Seeking Alpha · 04/01 17:48
Notable earnings before Tuesday's open
Seeking Alpha · 04/01 13:48
More
Webull provides a variety of real-time AIM stock news. You can receive the latest news about Aim Immunotech through multiple platforms. This information may help you make smarter investment decisions.
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.